GB2333704A - Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions - Google Patents
Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions Download PDFInfo
- Publication number
- GB2333704A GB2333704A GB9802050A GB9802050A GB2333704A GB 2333704 A GB2333704 A GB 2333704A GB 9802050 A GB9802050 A GB 9802050A GB 9802050 A GB9802050 A GB 9802050A GB 2333704 A GB2333704 A GB 2333704A
- Authority
- GB
- United Kingdom
- Prior art keywords
- contrasting
- paramagnetic metal
- complex
- metal ions
- ethylene diamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to contrasting compositions comprising a complex of one or more selected metal ions (viz paramagnetic metal ions, eg a Gd ion and/or a Mn ion) and a specific complexing agent (viz ethylene diamine disuccinic acid). The invention also relates to the use of these complexes for preparation of a contrasting agent for use in MRI methods. The invention also relates to methods of preparation of such contrasting compositions.
Description
Contrastino Compositions
Technical Field
The invention relates to contrasting compositions comprising a complex of one or more paramagnetic metal ions and a specific complexing agent.
Background to the Invention
Magnetic resonance imaging (MRI) has been developed in recent years for obtaining a map or image of the human body. In MRI the contrast of the images generated may be enhanced by introducing into the zone being imaged an agent, generally referred to as a contrast agent, which affects the nuclear spin equilibration characteristics of the nuclei (generally water protons in body tissues or fluids) which are responsible for the magnetic resonance signals from which the MR images are generated. Therefore, paramagnetic contrast agents have been given to patients prior to imaging.
A number of patents disclose paramagnetic NIRI contrast agents including, for example, US patents 4,647.447; 4,859,451; 4,957,939; 4,963,344; 5,021,216; 5.064636 and 5,120.527; and PCT application W092/2101 7 Paramagnetic agents of the type disclosed in these patents have been administered to the patient in the form of aqueous solutions. In addition, paramagnetic oil emulsions have been provided for MRI imaging in the gastro-intestinal tract as disclosed in US patents 5,064,636 and 5,120,527.
In the design of MRJ agents, strict attention must be given to a varies', o properties that will ultimately affect the physiological outcome apart from the ability to provide contrast enhancement. Two fundamental properties that must be considered are biocompatability and proton relaxation enhancement. Biocompatability is influenced by several factors including tonicity. stability (thermodynamic and kinetic), pharmacokinetics and biodistribution. Proton relaxation enhancement (or relaxi'ity) is chiefly governed by the choice of metal, the rotational correlation times and the accessibility, of the metal to surrounding water moiecules (rapid exchange of water with the bulk).
The lanthanide atom Gd(III), has generally been chosen as the metal atom for contrast agents because it has a high magnetic moment (112=63BM2), a symmetric electronic ground state. (S8), the largest paramagnetic dipole and the greatest pararnagnetic relaxivity of any element.
In the past decades the main aim has been to develop chelating agents which have an improved binding capacity for heavy metal ions. X ell-kno'n chelating agent thereto is. for example, EDTA and DTPA.
Gd(III) has been chelated with several substances to render the complex non-toxic.
To date, a number of chelators have been used, including diethylenetriaminepentaacetic (DTPA). 1,4,7,1 O-tetraazacyclododecane' N,N'N' N"' -tetracetic acid (DOTA), and derivatives thereof. See US patent nos.
4.647.447, 5,155,215. 5,087,440, 5,219,553, 5.188,816, 4,88-;,;63. 5,358,704, 5.636.or2 and Meyer et al..Invest.Radiol. 25:S53 (1990).
The water soluble Gd(DTPA)-chelate is stable, nontoxic, and one of the most widely used contrast enhancement agents in experimental and clinical imaging research. It has been in use for clinical use in adult patients since the late 1980's. It is an extraceilular agent that accumulates in tissue by perfusion dominated processes.
Image enhancement improvements using Gd(DTPA) are well documented in a number of applications (Runge et al.. Magn Reson. Imag. 3:85 (1991); Russell et awl..
AJR 152:813 (1989). Another chelator used in Gd contrast agents is the macrocyclic ligand 1.4,7,1 0-tetraazacyclododecane-N,N' N" ,N' " -tetracetic acid (DOTA).
Recently, the GdDOTA complex was approved as an MRI contrast agent in France.
The present inventors now have found that even those chelating agents which have a very high binding capacity for those metal ions. preferably used in MRI methods, such as Gd(III) and Mn(II) and iron, do not always perform very effectively.
The present inventors have now found that this can be due to the fact that these chelating agents do not just have a high binding capacity for heavy metal ions but also for other metal ions which may be present. It has been found that, for example. the presence of calcium ions can reduce the efficiency or effectiveness of certain chelating agents, such as DTPA and DOT A. The nature of the systems and the methods where the contrasting agents, containing the chelating agents, are used is such that the presence of calcium ions is unavoidable, in particular when the contrasting agent is used in bone tissue or blood . Thus, this can result in loss of the essential properties of the contrasting agent. Thus, there is a need for improved MRI contrast agents. which comprise stable complexes of the selected metal ions and a complexing agent.
However. the inventors have now found that EDDS is an excellent, specific complexing agents for forming complexes uith the selected paramagnetic metal ions. used for NIRI. such as GD(III) and 'V. ln(II) and iron, in particular in the presence of calcium. Thus, these specific agents are very effective complexing agents for use in contrasting compositions for use in MRI.
Summary of the Invention
In accordance with the present invention, there is provided a contrasting composition comprising a complex formed by of one or more selected paramagnetic metal ions. preferably Gd(III) andlor Mn(II) and ethylene diamine disuccinic acid (EDDS) complexing agent.
The invention also relates to the use of a complex comprising a complexing agent and a paramagnetic metal ion for preparation of contrasting compositions. Such contrasting compositions are used in diagnostic methods, such as MRI.
Detailed Description of the Invention Complexinlo Agents.
The complexing agents for use in the contrasting composition of the invention is N,
N ethylene diamine disuccinic acid or its salts (EDDS).
It is known that the (S,S) EDDS isomer is more readily biodegradable than the (RR) isomer. Thus, depending of the application of the aqueous compositions of the invention, it may be desirable to use only one of the isomers of EDDS. Furthermore, it can be preferred that a racemic mixture of the (R,R) EDDS and the (S,S) EDDS isomers are used in the aqueous compositions, for example because the racemic mixture is less expensive.
Paramaçnetic Metal Ion
The paramagnetic metal ion for use in the composition of the invention is preferably a lanthanide element of atomic numbers 58-70 or a transition metal of atomic numbers 21-29, 42 or 44, most preferably selected from a group consisting of Gd(II1), Mn(II), Fe(IIT) or (II) iron and dysprosium.
Contrasting Composition The contrasting composition of the invention comprises a complex of a paramagnetic metal ion and ethylene diamine disuccinic acid or salts thereof, as described herein.
The contrasting agent and the paramagentic metal ion are preferably present in the composition in a stoichiometric amount; it may be preferred that the contrasting agent is present in a stoichiometric excess.
The compositions according to this invention can preferably contain from 0.001 to 5.0 moles per litre and preferably from 0.1 to 1.2 moles per litre of the complex of the complexing agent and the paramagnetic metal ion.
The compositions of the invention are administered to patients for imaging in incorporation in the contrasting compositions of the invention amounts which are sufficient to yield the desired contrast, whereby n pically the amounts are calculated such that a dosages of from 0.00 l to 5.0 mmoles of the complex of the complexing agent and the paramagnetic metal ion, per kilogram of patient body weight are given
Additional Components
The compositions can comprise a variety of additional conventional pharmaceutical or veterinary formulation aids, for example stabilisers, antioxidants, buffers, pH adjusting agents, etc.
The compositions of the present invention may be in conventional pharmaceutical administration forms such as solutions, suspensions, dispersions, syrups, suppositories, etc. and solutions, suspensions and dispersions in physiologically acceptable carrier media, for example oils and/ or water for injections, will generally be preferred.
The contrast media according to the invention may therefore be formulated for administration using physiologically acceptable carrier as known in the art.
Highly preferred is the incorporation of a surfactant in the compositions of the invention. Surfactants are usually needed to form stable emulsions indicated above where the MRI agent has insufficient surfactant activity. Any suitable surfactant may be employed alone or in combination with other surfactants. For example, egg yolk phospholipids or Pluronics emulsifying agents may be used. Ploronics agents are block polymer polyols sold by Wyandotte, e.g., Pluronics F68, having a molecular weight of about 8.000, may be employed. Ethoxylates of cholesterol, diacyl glycerol and dialkyl ether glycerol are useful surfactants. Also, using backbones of cholesterol, diacyl glycerol or dialkyl ether glycerol, block copolymers are made by adding ethylene oxide, propylene oxide and ethylene oxide, in that order, in varying amounts to produce surfactant. In some applications for nonintravenous use, anionic or cationic surfactants may be used. The emulsions of this invention may contain alkylphosphoryl choline or allçylglycerophosphoryl choline surfactants described in
Kaufinan and Richard, US Serial No. 791, 420, filed November 13, 1991.
Anionic surfactants include alkyl or aryl sulfates, sulfonates, carboxylates or phosphates. Cationic surfactants include such as mono-, di-, tri- and tetraalkyl or aryl ammonium salts. Non-ionic surfactants include alkyl or aryl compounds, whose hydrophilic part consists of polyoxyethylene chains, sugar molecules, polyalcohol derivatives or other hydrophilic groups. Zwitter-ionic surfactants may have a combination of the above anionic or cationic groups, and whose hydrophobic part consists or any other polymer, such as polyisobutylene or polypropylene oxides.
The compositions can compnse as an additional component, a fluorochemical. These fluorochemicals are either highly fluorinated organic compounds or perfluorcarbon or fluorinated chemicals.
The compositions preferably comprise a oil. A large class of physiologically acceptable substances whether of mineral, vegetable, animal, essential or synthetic origin, can be used herein. Preferred can be, petroleumderived oils such as refined paraffin oil, oils derived from seeds or nuts, linseed oil, tung oil, safflower oil, soy bean oil, castor oil, cottonseed oil, coconut oil, palm oil and coconut oils and oils derived from fat such as tallow, lard, stearic acid and oleic acid. Included are some vegetable oils. such as olive, cottonseed, corn and peanut, as well as some special fish oils such as cod-liver, haliver, shark liver, and so forth which are used largely as medicines for their high vitamin content. A liquid fat oil such as a mono-,di-, or triglyceride. or a mixture thereof, is the preferred oil. Medium chain triglycerides also serve as useful oils according to this invention.
Process for Preparation of a Gadolinium-EDDS Complex
A stoichiometric equivalent of gadolinium oxide and ethylene diamine disuccinic acid, in 75:22:3 (V,VIV) CHCl3:CH3OH:H2O (w0.1 mole of complex of solvent) iss heated at reflux with stirring for 18-25 hours. After cooling to ambient temperature, the solution is filtered through Celite to remove trace Gd2O3. The filtrate is concentrated to yield an off-white solid or glass. The resulting solid is recrystallised from appropriate solvent. The resulting solid is dried in a vacuum oven at 500-650"C and 29mm Hg vacuum overnight Successfiil complexation is evident by the dissolution of Gtl203 into the organic solvent mix The complex can be detected by use of thin layer chromatography (mC), relative to the free ligand, and/ or infrared spectroscopy. Completion of the reaction could be monitored by TLC.
Upon completion of the reaction, aq. NaOH was used to neutralise the reaction mixture and precipitated NaCI was removed by filtration through Celite.
Claims (6)
- Claims 1.A contrasting composition comprising a complex formed by of one or more paramagnetic metal ions and ethylene diamine disuccinic acid complexing agent.
- 9. A composition according to claim 1 wherein the paramagnetic metal ion is a Gd ion and/or a Mn ion.
- 3. .N composition according to claim 1 or 2 wherein calcium ions are present.
- A. A contrasting composition according to claim 3, obtainable by a process comprising the addition of a paramagnetic metal ion and an EDDS complexing agent to an aqueous solution, comprising calcium ions.
- 5. Use of a complex formed by EDDS complexing agent and a paramagnetic metal ion for preparation of a contrasting composition according to any of claim 1 to 4 for use in a method of magnetic resonance imaging.
- 6. Use of a complex formed by ethylene diamine disuccinic acid and a paramagnetic metal ion for preparation of a contrasting composition according to any of claims 1 to 5, for use in a method of magnetic resonance imaging.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9802050A GB2333704A (en) | 1998-01-31 | 1998-01-31 | Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions |
PCT/IB1999/000117 WO1999038538A1 (en) | 1998-01-31 | 1999-01-25 | Mri contrast agents comprising ethylene diamine disuccinic acid as chelants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9802050A GB2333704A (en) | 1998-01-31 | 1998-01-31 | Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9802050D0 GB9802050D0 (en) | 1998-03-25 |
GB2333704A true GB2333704A (en) | 1999-08-04 |
Family
ID=10826199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9802050A Withdrawn GB2333704A (en) | 1998-01-31 | 1998-01-31 | Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2333704A (en) |
WO (1) | WO1999038538A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2465663A (en) * | 2008-11-26 | 2010-06-02 | Ge Healthcare As | X-ray contrast agent compositions comprising an iodinated X-ray contrast agent and ethylenediamine-N,N-disuccinic acid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
WO1995025159A1 (en) * | 1994-03-17 | 1995-09-21 | The Procter & Gamble Company | Bleach improvement with manganese ethylenediamine-n,n'-disuccinate |
US5550285A (en) * | 1994-07-11 | 1996-08-27 | Albemarle Corp | Method for producing calcium salts of [S,S]-ethylenediamine-N,N'-disuccinic acid |
US5741555A (en) * | 1995-05-22 | 1998-04-21 | The Dow Chemical Company | Succinic acid derivative degradable chelants, uses and compositions thereof |
DE19616992C1 (en) * | 1996-04-27 | 1997-09-11 | Analyticon Ges Fuer Chemische | Treating cytomegalovirus infections, e.g. in immuno-suppressed patients |
-
1998
- 1998-01-31 GB GB9802050A patent/GB2333704A/en not_active Withdrawn
-
1999
- 1999-01-25 WO PCT/IB1999/000117 patent/WO1999038538A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1999038538A1 (en) | 1999-08-05 |
GB9802050D0 (en) | 1998-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0414700B1 (en) | Contrast agents for magnetic resonance imaging | |
EP0436579B1 (en) | Chelate compositions | |
Misra et al. | Biological and clinical aspects of lanthanide coordination compounds | |
US5077037A (en) | Novel compositions for magnetic resonance imaging | |
CA2108362A1 (en) | Melanin-based agents for image enhancement | |
US5162109A (en) | Magnetic resonance imaging agents | |
WO1995028179A1 (en) | Contrast agents for diagnostic imaging | |
JPH07500823A (en) | Processed apatite particles for medical diagnostic imaging | |
JPH08509217A (en) | Treated calcium / oxyanion containing particles for medical diagnostic imaging | |
CA2077556A1 (en) | Lipophilic contrast agents for diagnostic image analysis | |
US5138040A (en) | Composition for magnetic resonance imaging | |
WO2008134289A2 (en) | High relaxivity coordinatively unsaturated lanthanide complexes | |
US6146615A (en) | Contrast agents for image enhancement in magnetic resonance imaging | |
GB2333704A (en) | Contrasting compositions for magnetic resonance imaging comprising a complex of ethylene diamine disuccinic acid and one or more paramagnetic metal ions | |
Carr et al. | Contrast agents in magnetic resonance imaging | |
CA2304461C (en) | Lipophilic metal complexes for necrosis and infarction imaging | |
US5290537A (en) | Compositions for magnetic resonance imaging | |
WO1997033625A2 (en) | Water-soluble lipophilic contrast agents | |
KR20220130155A (en) | Iron complexes and salts thereof as contrast agents for MRI | |
CA2096543A1 (en) | Alkoxyamide derivatized chelates for mri | |
Goldstein et al. | Contrast media for magnetic resonance imaging | |
US6294152B1 (en) | Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging | |
US5516503A (en) | Diagnostic composition comprising a binuclear complex, its method of preparation and its use in magnetic resonance imaging | |
US5985245A (en) | Contrast agents for MRI using a manganese compound and kojic acid | |
Els et al. | Nmr contrast enhancement of brain tumours: comparison of the blood brain barrier tracer GdDTPA and the tumour-selective contrast agent MnTPPS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |